Epicatechin‐mediated modulation of the Nrf2/HO‐1 pathway alleviates senile cerebral ischemic/reperfusion injury

• Published in: Food science & nutrition 2024-09, Vol.12 (9), p.6521-6533
• Main Authors: Jiang, Changyue, Zhuge, Xiangzhen, Li, Deli, Chen, Menghua, Hu, Wanxiang, Xie, Lu
• Format: Article
• Language: English
• Subjects: Aging; Animal models; Antibodies; Antioxidants; Apoptosis; Blood-brain barrier; Brain damage; Catechol; Cell culture; Cerebral blood flow; cerebral ischemia–reperfusion injury; Chemical activity; Chemical reactions; Dehydrogenases; Drug development; Epicatechin; Flavonoids; Glutathione; Heme oxygenase (decyclizing); Hydroxyl groups; Ischemia; Medicinal plants; Morphology; Neuroprotection; Nrf2/ARE; Occlusion; Older people; Original; Oxidative stress; Oxygen; Phenolic compounds; Phenols; Plant cells; Proteins; Quinone oxidoreductase; Quinones; Reactive oxygen species; Reperfusion; Software; Stroke; Superoxide dismutase
• ISSN: 2048-7177; 2048-7177
• DOI: 10.1002/fsn3.4253

Excessive reactive oxygen species (ROS) generated during cerebral ischemic reperfusion (CIRI) are crucial for subsequent tissue damage. However, despite the potential benefits of antioxidants reported in clinical applications, few have proven effective in treating CIRI, particularly in the elderly. Epicatechin (EC) is a catechol flavonoid monomer derived from natural tea plants. Multiple phenolic hydroxyl groups give it strong antioxidant properties, which can not only degrade ROS through chemical reactions between hydroxyl and ROS but also enhance the activity of antioxidant enzymes in cells, and it is easy to penetrate the blood–brain barrier. But its antagonistic effect on age‐related CIRI and potential medicinal value are still unknown. Nuclear factor erythroid 2‐related factor 2 (Nrf2) is the most important transcription factor regulating the expression of antioxidant proteins in the body. This study first compared the pathological differences of the Nrf2 system in CIRI between 2‐month‐old and 12‐month‐old Sprague–Dawley (SD) rats. Subsequently, EC was administered to 12‐month‐old rat models of middle cerebral artery occlusion and reperfusion (MCAO/R) and senescent SH‐SY5Y cell models subjected to oxygen glucose deprivation/reoxygenation (OGD/R). EC treatment improved cerebral morphology and function; increased p‐Nrf2, heme oxygenase‐1 (HO‐1), superoxide dismutase (SOD), and glutathione (GSH) expression; reduced infarct volume; and neuronal apoptosis in senescent rats. Moreover, EC enhanced cellular activity and the expression of p‐Nrf2, HO‐1, and quinone oxidoreductase‐1 (NQO‐1) while decreasing ROS and malondialdehyde (MDA) levels and mitigating apoptosis in senescent SH‐SY5Y cells. These effects were reversed upon si‐Nrf2. In sum, we confirm that EC exerts neuroprotective effects by upregulating Nrf2/ARE and reducing oxidative stress, suggesting that EC may be a promising drug for the treatment of senile cerebral apoplexy. This study also provides a scientific basis for the development and selection of new drugs for ischemic stroke in elderly patients. Epicatechin promotes the phosphorylation of Nrf2 into p‐Nrf2, thereby increasing HO‐1, SOD, and GSH expression and decreasing ROS and MDA. Based on the modulation of the Nrf2/HO‐1 pathway, EC mitigates oxidative stress‐induced ROS accumulation and associated oxidative damage, thus alleviating CIRI.